Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease (NCT01616680)
The purpose of this research is to test the safety and efficacy of brentuximab vedotin (also known as SGN-035) in patients with acute skin graft-versus-host disease or GVHD.
- Condition: Graft vs. Host Disease (GVHD)
- Phase: II
- Enrollment: 0
- Start: September 2012
- Estimated Primary Completion: June 2016 (Final data collection date for primary outcome measure)
- Last verified: June 2013
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.